When it comes to weight loss, we’re all after a magic bullet, a simple, stress-free way of shedding the excess pounds. And so for millions around the world, the arrival of the so-called GLP-1 class of ...

Systematic review suggests GLP-1 receptor agonists offer strong preclinical neuroprotection in nondiabetic ischemic stroke, ...

Photo credit: shutterstock.com/These trendy patches promise Ozempic-like results without the prescription but experts are skeptical If your social media feed is ...

The word microdosing might make you think of LSD and magic mushrooms, but the term has gained a totally new meaning in the Age of Ozempic. Microdosing—essentially, taking a smaller dose of something ...

For standard GLP-1 usage, Roslin said that patients are started with a low dose and titrated up to clinical effect. That starting weekly dose is usually 0.25 mg for semaglutide (Ozempic, Wegovy) and 2 ...

Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...

New research reveals how GLP-1 medications are reshaping the treatment landscape for conditions affecting the heart, kidney, liver, and more, hinting at a new era in chronic disease management.

Weight-loss drugs like semaglutide may melt fat, but at the cost of muscle mass. A new review reveals how to protect your strength while reaping the benefits. Study: Glucagon-like peptide-1 receptor ...

Pharmaceutical vending machine at an airport. Image by Tim Sandle. Pharmaceutical vending machine at an airport. Image by Tim Sandle. Can a new discovery usher in a new generation of GLP-1 peptides – ...

Drugs like Ozempic, known collectively as GLP-1 receptor agonists, have become more widely used in recent years. Though they ...

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...